Loading…
A dual-targeting approach to inhibit Brucella abortus replication in human cells
Brucella abortus is an intracellular bacterial pathogen and an etiological agent of the zoonotic disease known as brucellosis. Brucellosis can be challenging to treat with conventional antibiotic therapies and, in some cases, may develop into a debilitating and life-threatening chronic illness. We u...
Saved in:
Published in: | Scientific reports 2016-10, Vol.6 (1), p.35835-35835, Article 35835 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Brucella abortus
is an intracellular bacterial pathogen and an etiological agent of the zoonotic disease known as brucellosis. Brucellosis can be challenging to treat with conventional antibiotic therapies and, in some cases, may develop into a debilitating and life-threatening chronic illness. We used multiple independent assays of
in vitro
metabolism and intracellular replication to screen a library of 480 known bioactive compounds for novel
B. abortus
anti-infectives. Eighteen non-cytotoxic compounds specifically inhibited
B. abortus
replication in the intracellular niche, which suggests these molecules function by targeting host cell processes. Twenty-six compounds inhibited
B. abortus
metabolism in axenic culture, thirteen of which are non-cytotoxic to human host cells and attenuate
B. abortus
replication in the intracellular niche. The most potent non-cytotoxic inhibitors of intracellular replication reduce
B. abortus
metabolism in axenic culture and perturb features of mammalian cellular biology including mitochondrial function and receptor tyrosine kinase signaling. The efficacy of these molecules as inhibitors of
B. abortus
replication in the intracellular niche suggests “dual-target” compounds that coordinately perturb host and pathogen are promising candidates for development of improved therapeutics for intracellular infections. |
---|---|
ISSN: | 2045-2322 2045-2322 |
DOI: | 10.1038/srep35835 |